Impact of body composition on pharmacokinetics of doxorubicin in children: A Glaser Pediatric Research Network study

Patrick A. Thompson, Gary L. Rosner, Katherine K. Matthay, Theodore B. Moore, Lisa R. Bomgaars, Kenneth J. Ellis, Jamie Renbarger, Stacey L. Berg

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Purpose: We studied the relationship between doxorubicin pharmacokinetics and body composition in children with cancer. Patients and methods: Children between 1 and 21 years of age, receiving doxorubicin as an infusion of any duration <24 h on either a 1-day or 2-day schedule were eligible if they had no significant abnormality of liver function tests, their dose of doxorubicin was not based on ideal body weight or otherwise "capped," and they weighed ≥12 kg. Body composition was measured by dual-energy X-ray absorptiometry. Doxorubicin and doxorubicinol concentration in plasma were measured by high pressure liquid chromatography. NONMEM was used to perform pharmacokinetic model fitting and S-PLUS was used to perform a post hoc analysis to examine the effect of body composition on pharmacokinetic parameters. Results: Twenty-two subjects (16 male; 10 Hispanic, 10 Caucasian, 2 Asian) completed the study. The median age was 15.0 years (range 3.3-21.5), median weight was 51.5 kg (range 12.4-80), median BMI was 19.7 (range 13.2-30.0), and median body fat was 25% (range 15-36). The population mean clearance of doxorubicin was 420 ml/min/m2. Doxorubicinol but not doxorubicin clearance was lower in patients with body fat greater than 30%. Conclusions: Doxorubicinol clearance is decreased in children with >30% body fat. This finding is potentially important clinically, because doxorubicinol may contribute significantly to cardiac toxicity after doxorubicin administration. Further study of the body composition on doxorubicin and doxorubicinol pharmacokinetics and on clinical outcomes is warranted.

Original languageEnglish
Pages (from-to)243-251
Number of pages9
JournalCancer Chemotherapy and Pharmacology
Volume64
Issue number2
DOIs
StatePublished - Jul 2009

Fingerprint

Pediatrics
Pharmacokinetics
Body Composition
Doxorubicin
Chemical analysis
Research
Toxicity
Adipose Tissue
Fats
Neoplasms
adriamycinol

Keywords

  • Body composition
  • Doxorubicin
  • Doxorubicinol
  • Obesity
  • Pediatrics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Thompson, P. A., Rosner, G. L., Matthay, K. K., Moore, T. B., Bomgaars, L. R., Ellis, K. J., ... Berg, S. L. (2009). Impact of body composition on pharmacokinetics of doxorubicin in children: A Glaser Pediatric Research Network study. Cancer Chemotherapy and Pharmacology, 64(2), 243-251. https://doi.org/10.1007/s00280-008-0854-z

Impact of body composition on pharmacokinetics of doxorubicin in children : A Glaser Pediatric Research Network study. / Thompson, Patrick A.; Rosner, Gary L.; Matthay, Katherine K.; Moore, Theodore B.; Bomgaars, Lisa R.; Ellis, Kenneth J.; Renbarger, Jamie; Berg, Stacey L.

In: Cancer Chemotherapy and Pharmacology, Vol. 64, No. 2, 07.2009, p. 243-251.

Research output: Contribution to journalArticle

Thompson, Patrick A. ; Rosner, Gary L. ; Matthay, Katherine K. ; Moore, Theodore B. ; Bomgaars, Lisa R. ; Ellis, Kenneth J. ; Renbarger, Jamie ; Berg, Stacey L. / Impact of body composition on pharmacokinetics of doxorubicin in children : A Glaser Pediatric Research Network study. In: Cancer Chemotherapy and Pharmacology. 2009 ; Vol. 64, No. 2. pp. 243-251.
@article{cf7508677a5d46299aa695e855b2446a,
title = "Impact of body composition on pharmacokinetics of doxorubicin in children: A Glaser Pediatric Research Network study",
abstract = "Purpose: We studied the relationship between doxorubicin pharmacokinetics and body composition in children with cancer. Patients and methods: Children between 1 and 21 years of age, receiving doxorubicin as an infusion of any duration <24 h on either a 1-day or 2-day schedule were eligible if they had no significant abnormality of liver function tests, their dose of doxorubicin was not based on ideal body weight or otherwise {"}capped,{"} and they weighed ≥12 kg. Body composition was measured by dual-energy X-ray absorptiometry. Doxorubicin and doxorubicinol concentration in plasma were measured by high pressure liquid chromatography. NONMEM was used to perform pharmacokinetic model fitting and S-PLUS was used to perform a post hoc analysis to examine the effect of body composition on pharmacokinetic parameters. Results: Twenty-two subjects (16 male; 10 Hispanic, 10 Caucasian, 2 Asian) completed the study. The median age was 15.0 years (range 3.3-21.5), median weight was 51.5 kg (range 12.4-80), median BMI was 19.7 (range 13.2-30.0), and median body fat was 25{\%} (range 15-36). The population mean clearance of doxorubicin was 420 ml/min/m2. Doxorubicinol but not doxorubicin clearance was lower in patients with body fat greater than 30{\%}. Conclusions: Doxorubicinol clearance is decreased in children with >30{\%} body fat. This finding is potentially important clinically, because doxorubicinol may contribute significantly to cardiac toxicity after doxorubicin administration. Further study of the body composition on doxorubicin and doxorubicinol pharmacokinetics and on clinical outcomes is warranted.",
keywords = "Body composition, Doxorubicin, Doxorubicinol, Obesity, Pediatrics, Pharmacokinetics",
author = "Thompson, {Patrick A.} and Rosner, {Gary L.} and Matthay, {Katherine K.} and Moore, {Theodore B.} and Bomgaars, {Lisa R.} and Ellis, {Kenneth J.} and Jamie Renbarger and Berg, {Stacey L.}",
year = "2009",
month = "7",
doi = "10.1007/s00280-008-0854-z",
language = "English",
volume = "64",
pages = "243--251",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Impact of body composition on pharmacokinetics of doxorubicin in children

T2 - A Glaser Pediatric Research Network study

AU - Thompson, Patrick A.

AU - Rosner, Gary L.

AU - Matthay, Katherine K.

AU - Moore, Theodore B.

AU - Bomgaars, Lisa R.

AU - Ellis, Kenneth J.

AU - Renbarger, Jamie

AU - Berg, Stacey L.

PY - 2009/7

Y1 - 2009/7

N2 - Purpose: We studied the relationship between doxorubicin pharmacokinetics and body composition in children with cancer. Patients and methods: Children between 1 and 21 years of age, receiving doxorubicin as an infusion of any duration <24 h on either a 1-day or 2-day schedule were eligible if they had no significant abnormality of liver function tests, their dose of doxorubicin was not based on ideal body weight or otherwise "capped," and they weighed ≥12 kg. Body composition was measured by dual-energy X-ray absorptiometry. Doxorubicin and doxorubicinol concentration in plasma were measured by high pressure liquid chromatography. NONMEM was used to perform pharmacokinetic model fitting and S-PLUS was used to perform a post hoc analysis to examine the effect of body composition on pharmacokinetic parameters. Results: Twenty-two subjects (16 male; 10 Hispanic, 10 Caucasian, 2 Asian) completed the study. The median age was 15.0 years (range 3.3-21.5), median weight was 51.5 kg (range 12.4-80), median BMI was 19.7 (range 13.2-30.0), and median body fat was 25% (range 15-36). The population mean clearance of doxorubicin was 420 ml/min/m2. Doxorubicinol but not doxorubicin clearance was lower in patients with body fat greater than 30%. Conclusions: Doxorubicinol clearance is decreased in children with >30% body fat. This finding is potentially important clinically, because doxorubicinol may contribute significantly to cardiac toxicity after doxorubicin administration. Further study of the body composition on doxorubicin and doxorubicinol pharmacokinetics and on clinical outcomes is warranted.

AB - Purpose: We studied the relationship between doxorubicin pharmacokinetics and body composition in children with cancer. Patients and methods: Children between 1 and 21 years of age, receiving doxorubicin as an infusion of any duration <24 h on either a 1-day or 2-day schedule were eligible if they had no significant abnormality of liver function tests, their dose of doxorubicin was not based on ideal body weight or otherwise "capped," and they weighed ≥12 kg. Body composition was measured by dual-energy X-ray absorptiometry. Doxorubicin and doxorubicinol concentration in plasma were measured by high pressure liquid chromatography. NONMEM was used to perform pharmacokinetic model fitting and S-PLUS was used to perform a post hoc analysis to examine the effect of body composition on pharmacokinetic parameters. Results: Twenty-two subjects (16 male; 10 Hispanic, 10 Caucasian, 2 Asian) completed the study. The median age was 15.0 years (range 3.3-21.5), median weight was 51.5 kg (range 12.4-80), median BMI was 19.7 (range 13.2-30.0), and median body fat was 25% (range 15-36). The population mean clearance of doxorubicin was 420 ml/min/m2. Doxorubicinol but not doxorubicin clearance was lower in patients with body fat greater than 30%. Conclusions: Doxorubicinol clearance is decreased in children with >30% body fat. This finding is potentially important clinically, because doxorubicinol may contribute significantly to cardiac toxicity after doxorubicin administration. Further study of the body composition on doxorubicin and doxorubicinol pharmacokinetics and on clinical outcomes is warranted.

KW - Body composition

KW - Doxorubicin

KW - Doxorubicinol

KW - Obesity

KW - Pediatrics

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=67349169750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349169750&partnerID=8YFLogxK

U2 - 10.1007/s00280-008-0854-z

DO - 10.1007/s00280-008-0854-z

M3 - Article

C2 - 19020877

AN - SCOPUS:67349169750

VL - 64

SP - 243

EP - 251

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -